AUXL Insider Trading
AUXL | Market Equity
Comprehensive Trading Performance Summary
The investment history of corporate insiders at AUXL provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Market Equity sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2014-12-09 00:19 | 2014-12-05 | MCKEE WILLIAM | Director | OPT+S | $34.00 | 18,000 | $612,000 | 10,000 | 0.0% |
| 2014-12-09 00:18 | 2014-12-05 | Lurker Nancy | Director | OPT+S | $34.00 | 32,430 | $1,102,620 | 10,000 | 0.0% |
| 2014-12-09 00:16 | 2014-12-05 | ADAMS ADRIAN | Director, Officer - CEO and President | OPT+S | $33.97 | 40,000 | $1,358,704 | 217,778 | 0.0% |
| 2014-12-09 00:14 | 2014-12-04 | FRIEDMAN PAUL A | Director | OPT+S | $33.73 | 29,689 | $1,001,404 | 10,361 | 0.0% |
| 2014-12-05 00:05 | 2014-12-02 | FETZER OLIVER | Director | OPT+S | $34.02 | 100,000 | $3,401,640 | 19,197 | 0.0% |
| 2014-12-05 00:03 | 2014-12-02 | CLASSON ROLF A | Director | OPT+S | $33.81 | 279,135 | $9,436,522 | 10,000 | 0.0% |
| 2014-11-26 18:55 | 2014-11-25 | JOBES ELIZABETH VARKI | Officer - Chief Compliance Officer | OPT+S | $34.04 | 27,802 | $946,274 | 13,767 | 0.0% |
| 2014-11-26 18:54 | 2014-11-25 | Tursi James Patrick | Officer - Chief Medical Officer | OPT+S | $34.12 | 13,713 | $467,929 | 31,904 | 0.0% |
| 2014-11-25 00:59 | 2014-11-20 | WILLS ALAN | Officer - EVP, Corporate Development | OPT+S | $33.18 | 156,592 | $5,195,300 | 30,743 | 0.0% |
| 2014-11-25 00:57 | 2014-11-20 | Tursi James Patrick | Officer - Chief Medical Officer | OPT+S | $33.19 | 74,648 | $2,477,567 | 35,055 | 0.0% |
| 2014-11-25 00:56 | 2014-11-21 | KOVEN ANDREW I | Officer - EVP, CAO, GC and Secretary | OPT+S | $33.43 | 139,683 | $4,669,924 | 38,721 | 0.0% |
| 2014-11-25 00:54 | 2014-11-20 | Glickman Mark A | Officer - EVP - Sales and Marketing | OPT+S | $33.17 | 47,952 | $1,590,333 | 27,911 | 0.0% |
| 2014-11-25 00:52 | 2014-11-21 | Armstrong Jennifer Lou | Officer - Senior Vice President, HR | OPT+S | $33.50 | 75,803 | $2,539,105 | 14,874 | 0.0% |
| 2014-03-17 23:44 | 2014-03-14 | DEL TITO BENJAMIN J JR | Officer - EVP, Reg Affairs & Project Mgt | OPT+S | $29.50 | 32,032 | $945,014 | 5,798 | 0.0% |
| 2014-03-07 00:42 | 2014-03-05 | CLASSON ROLF A | Director | OPT+S | $31.85 | 10,000 | $318,477 | 22,937 | 0.0% |
| 2013-12-17 01:07 | 2013-12-13 | DEL TITO BENJAMIN J JR | Officer - EVP, Reg Affairs & Project Mgt | OPT+S | $20.50 | 4,602 | $94,341 | 4,064 | 0.0% |
| 2013-12-13 00:05 | 2013-12-11 | Fickenscher James E | Officer - Chief Financial Officer | OPT+S | $20.37 | 71,067 | $1,447,450 | 45,132 | 0.0% |
| 2013-08-15 23:42 | 2013-08-15 | FETZER OLIVER | Director | SELL | $18.75 | 1,900 | $35,634 | 14,197 | -11.8% |
| 2013-05-22 23:50 | 2013-05-20 | MCKEE WILLIAM | Director | SELL | $15.10 | 2,000 | $30,209 | 8,000 | -20.0% |
| 2012-12-17 17:53 | 2012-12-14 | ADAMS ADRIAN | Director, Officer - CEO and President | BUY | $0.00 | 56,000 | $0 | 56,579 | +9,671.8% |
| 2012-06-27 00:15 | 2012-06-25 | DEL TITO BENJAMIN J JR | Officer - EVP, Reg Affairs & Project Mgt | OPT+S | $25.01 | 12,682 | $317,155 | 4,470 | 0.0% |
| 2012-06-08 18:05 | 2012-06-06 | DEL TITO BENJAMIN J JR | Officer - EVP, Reg Affairs & Project Mgt | OPT+S | $22.55 | 6,000 | $135,302 | 2,024 | 0.0% |
| 2012-03-02 01:01 | 2012-02-28 | Brandt Peter C. | Director | BUY | $20.10 | 10,000 | $200,998 | 10,000 | +100.0% |
| 2011-11-08 01:05 | 2011-11-03 | Fickenscher James E | Officer - Chief Financial Officer | BUY | $15.54 | 1,610 | $25,024 | 26,839 | +6.4% |
| 2011-10-12 04:33 | 2011-10-07 | ANIDO ARMANDO | Director, Officer - CEO & President | OPT+S | $14.23 | 5,275 | $75,046 | 13,653 | 0.0% |
| 2011-08-03 23:55 | 2011-08-01 | 14159 capital (GP), LLC | 10% owner | SELL | $17.99 | 17,079 | $307,234 | 132,889 | -11.4% |
| 2011-08-03 23:54 | 2011-08-01 | Baker Biotech Capital (GP), LLC | 10% owner | SELL | $17.99 | 108,570 | $1,953,066 | 844,839 | -11.4% |
| 2011-08-03 23:53 | 2011-08-01 | Baker Brothers Life Sciences Capital (GP), LLC | 10% owner | SELL | $17.99 | 696,053 | $12,521,297 | 5,416,304 | -11.4% |
| 2011-08-03 23:53 | 2011-08-01 | Baker / Tisch Capital (GP), LLC | 10% owner | SELL | $17.99 | 8,652 | $155,641 | 67,322 | -11.4% |
| 2011-07-13 02:49 | 2011-07-08 | ANIDO ARMANDO | Director, Officer - CEO & President | OPT+S | $20.30 | 5,275 | $107,101 | 13,653 | 0.0% |
| 2011-04-05 03:36 | 2011-03-08 | ANIDO ARMANDO | Director, Officer - CEO & President | OPT+S | $23.02 | 10,555 | $242,993 | 13,653 | 0.0% |
| 2011-04-01 01:01 | 2011-03-30 | 14159 capital (GP), LLC | 10% owner | BUY | $21.98 | 3,911 | $85,963 | 149,968 | +2.7% |
| 2011-04-01 00:59 | 2011-03-30 | Baker Bros. Capital (GP), LLC | 10% owner | BUY | $21.98 | 309 | $6,792 | 6,992 | +4.6% |
| 2011-04-01 00:50 | 2011-03-29 | Baker Brothers Life Sciences Capital (GP), LLC | 10% owner | BUY | $21.98 | 332,000 | $7,298,057 | 6,105,365 | +5.8% |
| 2011-03-11 04:04 | 2011-03-08 | 14159 capital (GP), LLC | 10% owner | BUY | $22.86 | 5,693 | $130,148 | 146,057 | +4.1% |
| 2011-03-11 04:03 | 2011-03-08 | Baker Brothers Life Sciences Capital (GP), LLC | 10% owner | BUY | $22.90 | 988,489 | $22,640,451 | 5,773,365 | +20.7% |
| 2011-03-10 03:15 | 2011-03-08 | ANIDO ARMANDO | Director, Officer - CEO & President | OPT+S | $23.02 | 10,555 | $242,993 | 16,072 | 0.0% |
| 2011-01-13 05:33 | 2011-01-10 | ANIDO ARMANDO | Director, Officer - CEO & President | OPT+S | $23.22 | 10,555 | $245,050 | 16,072 | 0.0% |
| 2010-08-30 23:47 | 2010-08-26 | 14159 capital (GP), LLC | 10% owner | BUY | $25.51 | 3,052 | $77,843 | 140,364 | +2.2% |
| 2010-08-30 23:45 | 2010-08-26 | Baker Brothers Life Sciences Capital (GP), LLC | 10% owner | BUY | $25.51 | 110,547 | $2,819,557 | 4,784,876 | +2.4% |
| 2010-04-29 01:33 | 2010-04-26 | DEL TITO BENJAMIN J JR | Officer - EVP, Reg Affairs & Project Mgt | OPT+S | $35.67 | 7,318 | $261,061 | 4,299 | 0.0% |
| 2010-04-22 01:30 | 2010-04-19 | Bescherer Edwin A Jr | Director | OPT+S | $36.48 | 6,250 | $228,008 | 0 | 0.0% |
| 2010-04-15 02:05 | 2010-04-12 | ANIDO ARMANDO | Director, Officer - CEO & President | OPT+S | $33.07 | 30,000 | $992,115 | 101,689 | 0.0% |
| 2010-03-12 03:19 | 2010-03-09 | 14159 capital (GP), LLC | 10% owner | BUY | $32.92 | 4,977 | $163,855 | 137,312 | +3.8% |
| 2010-03-12 03:15 | 2010-03-09 | Baker Brothers Life Sciences Capital (GP), LLC | 10% owner | BUY | $32.47 | 130,295 | $4,230,640 | 4,674,329 | +2.9% |
| 2009-09-30 04:36 | 2009-09-25 | Bescherer Edwin A Jr | Director | OPT+S | $34.83 | 27,600 | $961,305 | 3,000 | 0.0% |
| 2009-09-17 02:17 | 2009-09-14 | Stacey Jennifer Evans | Officer - Executive VP & General Counsel | OPT+S | $35.43 | 6,333 | $224,390 | 9,382 | 0.0% |
| 2009-09-17 02:16 | 2009-09-14 | Graham Roger D Jr | Officer - Executive VP, Sales & Mktg | OPT+S | $35.74 | 12,950 | $462,781 | 12,832 | 0.0% |
| 2009-09-17 02:14 | 2009-09-14 | Fickenscher James E | Officer - Chief Financial Officer | OPT+S | $30.70 | 4,000 | $122,811 | 17,751 | 0.0% |
| 2009-09-11 01:37 | 2009-09-08 | Fickenscher James E | Officer - Chief Financial Officer | OPT+S | $30.00 | 4,000 | $120,007 | 17,751 | 0.0% |
How to Interpret $AUXL Trades
Not every insider transaction in AUXL is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $AUXL shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for AUXL
Insider activity data for AUXL is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $AUXL, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.